State-of-the-art management of nasopharyngeal carcinoma: Current and future directions

M. Agulnik, L. L. Siu*

*Corresponding author for this work

Research output: Contribution to journalShort survey

53 Scopus citations

Abstract

Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer. Approximately 70% of patients with newly diagnosed NPC present with locally advanced disease. Phase III clinical trials support the addition of chemotherapy to radiotherapy for the initial treatment of these patients. Once metastatic disease develops, practices become varied. Further experience needs to be gained with both targeted therapies and immunotherapy to gauge whether they will improve treatment outcomes in NPC.

Original languageEnglish (US)
Pages (from-to)799-806
Number of pages8
JournalBritish Journal of Cancer
Volume92
Issue number5
DOIs
StatePublished - Mar 14 2005

Keywords

  • Chemotherapy
  • Immunotherapy
  • Molecular targeted agents
  • Nasopharyngeal carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'State-of-the-art management of nasopharyngeal carcinoma: Current and future directions'. Together they form a unique fingerprint.

  • Cite this